Defined lipid analogues induce transient channels to facilitate drug-membrane traversal and circumvent cancer therapy resistance

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Van Hell, Albert J ^a   Melo, Manuel N ^a   Van Blitterswijk, Wim J ^a   Gueth, Dayana M ^b   Braumuller, Tanya M ^b   Pedrosa, Lilia R C ^c   Song, Ji Ying ^c   Marrink, Siewert J ^d,e   Koning, Gerben A ^a   Jonkers, Jos ^f   Verheij, Marcel ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b Molecular Pathology ^*  (Netherlands)

^c Molecular Pathology   (Netherlands)

^d Experimental Animal Pathology   (Netherlands)

^e UNIVERSITY OF GRONINGEN   (Netherlands)

^f Department of Surgery   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; GLYCEROPHOSPHOLIPID; GLYCOSPHINGOLIPID; LIPOSOME;

ANIMAL; ARTICLE; BIOLOGICAL MODEL; CELL LINE; CELL MEMBRANE; CELL PROLIFERATION; CHEMISTRY; DISEASE MODEL; DRUG RESISTANCE; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; LIPID BILAYER; METABOLISM; MORTALITY; MOUSE; PATHOLOGY; TRANSPORT AT THE CELLULAR LEVEL; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL LINE; CELL MEMBRANE; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GLYCEROPHOSPHOLIPIDS; GLYCOSPHINGOLIPIDS; LIPID BILAYERS; LIPOSOMES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MODELS, BIOLOGICAL; TUMOR BURDEN;

EID: 84902941080     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep01949     Document Type: Article

References (35)

1. van Meer, G., Voelker, D. R. &Feigenson, G.W.Membrane lipids: where they are and how they behave. Nat. Rev. Mol. Cell. Biol. 9, 112-124 (2008)
2. Finkelstein, A.Water and nonelectrolyte permeability of lipid bilayer membranes. J. Gen. Physiol. 68, 127-135 (1976)
3. Al-Awqati, Q. One hundred years of membrane permeability: does Overton still rule? Nat. Cell. Biol. 1, E201-202 (1999)
4. Dobson, P. D. &Kell, D. B. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat. Rev. Drug. Discov. 7, 205-220 (2008)
5. Sugano, K. et al. Coexistence of passive and carrier-mediated processes in drug transport. Nat. Rev. Drug. Discov. 9, 597-614 (2010)
6. Lankelma, J. et al. Doxorubicin Gradients in Human Breast Cancer. Clin. Cancer Res. 5, 1703-1707 (1999)
7. Regev, R. &Eytan, G. D. Flip-flop of doxorubicin across erythrocyte and lipid membranes. Biochem. Pharmacol. 54, 1151-1158 (1997)
8. Papahadjopoulos, D. et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA 88, 11460-11464 (1991)
9. O'Brien, M. E. et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment ofmetastatic breast cancer. Ann. Oncol. 15, 440-449 (2004)
10. van Lummel, M. et al. Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors. FASEB J. 25, 280-289 (2011)
11. Veldman, R. J., Zerp, S., van Blitterswijk, W. J. &Verheij, M. N-hexanoylsphingomyelin potentiates in vitro doxorubicin cytotoxicity by enhancing its cellular influx. Br. J. Cancer 90, 917-925 (2004)
12. Israelachvili, J. N., Mitchell, D. J. &Ninham, B. W. Theory of self-Assembly of hydrocarbon amphiphiles into micelles and bilayers. J. Chem. Soc., Faraday Trans. 2 72, 1525-1568 (1976)
13. Orsi, M. &Essex, J. W. Permeability of drugs and hormones through a lipid bilayer: insights from dual-resolution molecular dynamics. Soft Matter 6, 3797-3808 (2010)
14. de Wolf, F. A. et al. Comparable interaction of doxorubicin with various acidic phospholipids results in changes of lipid order and dynamics. Biochim. Biophys. Acta 1096, 67-80 (1990)
15. Derksen, P. W. et al. Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice. Dis. Model. Mech. 4, 347-358 (2011)
16. Derksen, P. W. et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 10, 437-449 (2006)
17. Veldman, R. J. et al. Coformulated N-octanoyl-glucosylceramide improves cellular delivery and cytotoxicity of liposomal doxorubicin. J. Pharmacol. Exp. Ther. 315, 704-710 (2005)
18. Futerman, A. H. &Pagano, R. E. Use of N-([1-14C]hexanoyl)-D-erythrosphingolipids to assay sphingolipid metabolism. Methods Enzymol. 209, 437-446 (1992)
19. Nurgalieva, Z., Liu, C. C. &Du, X. L. Chemotherapy use and risk of bone marrow suppression in a large population-based cohort of older women with breast and ovarian cancer. Med. Oncol. (2010)
20. Steinberg, D. Anemia and cancer. CA: Cancer J. Clin. 39, 296-304 (1989)
21. Xiong, G., Chen, Y. &Arriaga, E. A. Measuring the Doxorubicin Content of Single Nuclei by Micellar Electrokinetic Capillary Chromatography with Laser-Induced Fluorescence Detection. Anal. Chem. 77, 3488-3493 (2005)
22. Gabizon, A., Shmeeda, H. &Barenholz, Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin. Pharm. 42, 419-436 (2003)
23. Fang, J., Nakamura, H. &Maeda, H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Del. Rev. 63, 136-151 (2011)
24. Borst, P., Jonkers, J. &Rottenberg, S. What Makes Tumors Multidrug Resistant? Cell Cycle 6, 2782-2787 (2007)
25. Regev, R., Yeheskely-Hayon, D., Katzir, H. &Eytan, G. D. Transport of anthracyclines and mitoxantrone across membranes by a flip-flop mechanism. Biochem. Pharmacol. 70, 161-169 (2005)
26. Lingwood, D. &Simons, K. Lipid rafts as a membrane-organizing principle. Science 327, 46-50 (2010)
27. Adler, M. &Tritton, T. R. Fluorescence depolarization measurements on oriented membranes. Biophys. J. 53, 989-1005 (1988)
28. Harkewicz, R. &Dennis, E. A. Applications of Mass Spectrometry to Lipids and Membranes. Ann. Rev. Biochem. 80, 301-325 (2011)
29. van Meer, G. Atherosclerosis, endothelium and plasma membrane lipid polarity. Agents Actions Suppl. 26, 15-25 (1988)
30. Sampaio, J. L. et al.Membrane lipidome of an epithelial cell line. Proc. Natl. Acad. Sci. USA 108, 1903-1907 (2010)
31. Harkewicz, R. &Dennis, E. A. Applications of mass spectrometry to lipids and membranes. Annu. Rev. Biochem. 80, 301-325 (2011)
32. Shevchenko, A. &Simons, K. Lipidomics: coming to grips with lipid diversity. Nat Rev. Mol. Cell. Biol. 11, 593-598 (2010)
33. Harris, L. et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94, 25-36 (2002)
34. Lorusso, D. et al. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann. Oncol. 18, 1159-1164 (2007)
35. van Meer, G., Halter, D., Sprong, H., Somerharju, P. &Egmond, M. R. ABC lipid transporters: extruders, flippases, or flopless activators? FEBS Lett. 580, 1171-1177 (2006)